Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate
Purpose: To evaluate the outcomes of ruthenium-106 ( 106 Ru) brachytherapy in terms of radiation parameters in patients with thick uveal melanomas. Material and methods: Medical records of 51 patients with thick (thickness ≥ 7 mm and < 11 mm) uveal melanoma treated with 106 Ru brachytherapy...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2016-02-01
|
| Series: | Journal of Contemporary Brachytherapy |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Ruthenium-106-brachytherapy-for-thick-uveal-melanoma-reappraisal-of-apex-and-base-dose-radiation-and-dose-rate,54,26937,1,1.html |
| _version_ | 1811218012554919936 |
|---|---|
| author | Masood Naseripour Ramin Jaberi Ahad Sedaghat Zohreh Azma Marzieh Nojomi Khalil Ghasemi Falavarjani Hossein Nazari |
| author_facet | Masood Naseripour Ramin Jaberi Ahad Sedaghat Zohreh Azma Marzieh Nojomi Khalil Ghasemi Falavarjani Hossein Nazari |
| author_sort | Masood Naseripour |
| collection | DOAJ |
| description | Purpose: To evaluate the outcomes of ruthenium-106 ( 106 Ru) brachytherapy in terms of radiation parameters in patients with thick uveal melanomas.
Material and methods: Medical records of 51 patients with thick (thickness ≥ 7 mm and < 11 mm) uveal melanoma treated with 106 Ru brachytherapy during a ten-year period were reviewed. Radiation parameters, tumor regression, best corrected visual acuity (BCVA), and treatment-related complications were assessed.
Results: Fifty one eyes of 51 consecutive patients including 25 men and 26 women with a mean age of 50.5 ± 15.2 years were enrolled. Patients were followed for 36.1 ± 26.5 months (mean ± SD). Mean radiation dose to tumor apex and to sclera were 71 (± 19.2) Gy and 1269 (± 168.2) Gy. Radiation dose rates to tumor apex and to sclera were 0.37 (± 0.14) Gy/h and 6.44 (± 1.50) Gy/h. Globe preservation was achieved in 82.4%. Preoperative mean tumor thickness of 8.1 (± 0.9) mm decreased to 4.5 (± 1.6) mm, 3.4 (± 1.4) mm, and 3.0 (± 1.46) mm at 12, 24, and 48 months after brachytherapy (p = 0.03). Four eyes that did not show regression after 6 months of brachytherapy were enucleated. Secondary enucleation was performed in 5 eyes because of tumor recurrence or neovascular glaucoma. Tumor recurrence was evident in 6 (11.8%) patients. Mean Log MAR (magnification requirement) visual acuity declined from 0.75 (± 0.63) to 0.94 (± 0.5) (p = 0.04). Best corrected visual acuity of 20/200 or worse was recorded in 37% of the patients at the time of diagnosis and 61.7% of the patients at last exam (p = 0.04). Non-proliferative and proliferative radiation-induced retinopathy was observed in 20 and 7 eyes.
Conclusions : Thick uveal melanomas are amenable to 106 Ru brachytherapy with less than recommended apex radiation dose and dose rates. |
| first_indexed | 2024-04-12T07:03:59Z |
| format | Article |
| id | doaj.art-7e34618faffb498e90f3e70e2fc2105c |
| institution | Directory Open Access Journal |
| issn | 1689-832X 2081-2841 |
| language | English |
| last_indexed | 2024-04-12T07:03:59Z |
| publishDate | 2016-02-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Journal of Contemporary Brachytherapy |
| spelling | doaj.art-7e34618faffb498e90f3e70e2fc2105c2022-12-22T03:42:56ZengTermedia Publishing HouseJournal of Contemporary Brachytherapy1689-832X2081-28412016-02-0181667310.5114/jcb.2016.5781826937Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rateMasood NaseripourRamin JaberiAhad SedaghatZohreh AzmaMarzieh NojomiKhalil Ghasemi FalavarjaniHossein NazariPurpose: To evaluate the outcomes of ruthenium-106 ( 106 Ru) brachytherapy in terms of radiation parameters in patients with thick uveal melanomas. Material and methods: Medical records of 51 patients with thick (thickness ≥ 7 mm and < 11 mm) uveal melanoma treated with 106 Ru brachytherapy during a ten-year period were reviewed. Radiation parameters, tumor regression, best corrected visual acuity (BCVA), and treatment-related complications were assessed. Results: Fifty one eyes of 51 consecutive patients including 25 men and 26 women with a mean age of 50.5 ± 15.2 years were enrolled. Patients were followed for 36.1 ± 26.5 months (mean ± SD). Mean radiation dose to tumor apex and to sclera were 71 (± 19.2) Gy and 1269 (± 168.2) Gy. Radiation dose rates to tumor apex and to sclera were 0.37 (± 0.14) Gy/h and 6.44 (± 1.50) Gy/h. Globe preservation was achieved in 82.4%. Preoperative mean tumor thickness of 8.1 (± 0.9) mm decreased to 4.5 (± 1.6) mm, 3.4 (± 1.4) mm, and 3.0 (± 1.46) mm at 12, 24, and 48 months after brachytherapy (p = 0.03). Four eyes that did not show regression after 6 months of brachytherapy were enucleated. Secondary enucleation was performed in 5 eyes because of tumor recurrence or neovascular glaucoma. Tumor recurrence was evident in 6 (11.8%) patients. Mean Log MAR (magnification requirement) visual acuity declined from 0.75 (± 0.63) to 0.94 (± 0.5) (p = 0.04). Best corrected visual acuity of 20/200 or worse was recorded in 37% of the patients at the time of diagnosis and 61.7% of the patients at last exam (p = 0.04). Non-proliferative and proliferative radiation-induced retinopathy was observed in 20 and 7 eyes. Conclusions : Thick uveal melanomas are amenable to 106 Ru brachytherapy with less than recommended apex radiation dose and dose rates.https://www.termedia.pl/Ruthenium-106-brachytherapy-for-thick-uveal-melanoma-reappraisal-of-apex-and-base-dose-radiation-and-dose-rate,54,26937,1,1.htmlbrachytherapy radiation <sup>106</sup>Ru plaque uveal melanoma |
| spellingShingle | Masood Naseripour Ramin Jaberi Ahad Sedaghat Zohreh Azma Marzieh Nojomi Khalil Ghasemi Falavarjani Hossein Nazari Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate Journal of Contemporary Brachytherapy brachytherapy radiation <sup>106</sup>Ru plaque uveal melanoma |
| title | Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate |
| title_full | Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate |
| title_fullStr | Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate |
| title_full_unstemmed | Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate |
| title_short | Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate |
| title_sort | ruthenium 106 brachytherapy for thick uveal melanoma reappraisal of apex and base dose radiation and dose rate |
| topic | brachytherapy radiation <sup>106</sup>Ru plaque uveal melanoma |
| url | https://www.termedia.pl/Ruthenium-106-brachytherapy-for-thick-uveal-melanoma-reappraisal-of-apex-and-base-dose-radiation-and-dose-rate,54,26937,1,1.html |
| work_keys_str_mv | AT masoodnaseripour ruthenium106brachytherapyforthickuvealmelanomareappraisalofapexandbasedoseradiationanddoserate AT raminjaberi ruthenium106brachytherapyforthickuvealmelanomareappraisalofapexandbasedoseradiationanddoserate AT ahadsedaghat ruthenium106brachytherapyforthickuvealmelanomareappraisalofapexandbasedoseradiationanddoserate AT zohrehazma ruthenium106brachytherapyforthickuvealmelanomareappraisalofapexandbasedoseradiationanddoserate AT marziehnojomi ruthenium106brachytherapyforthickuvealmelanomareappraisalofapexandbasedoseradiationanddoserate AT khalilghasemifalavarjani ruthenium106brachytherapyforthickuvealmelanomareappraisalofapexandbasedoseradiationanddoserate AT hosseinnazari ruthenium106brachytherapyforthickuvealmelanomareappraisalofapexandbasedoseradiationanddoserate |